Therapy of Ischemic Cerebral Vascular Disease

Martin M. Pincus; Michael Hennerici; Wolfgang Rautenberg; Lawrence J. Saidman; J. P. Kistler; Allan H. Ropper; Roberto C. Heros

doi:10.1056/NEJM198410253111715

Therapy of Ischemic Cerebral Vascular Disease

Martin M. Pincus, Michael Hennerici, Wolfgang Rautenberg, Lawrence J. Saidman, J. P. Kistler, Allan H. Ropper, Roberto C. Heros

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Abstract

To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

Original language	English (US)
Pages (from-to)	1124-1125
Number of pages	2
Journal	New England Journal of Medicine
Volume	311
Issue number	17
DOIs	https://doi.org/10.1056/NEJM198410253111715
State	Published - Oct 25 1984
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM198410253111715

Fingerprint Dive into the research topics of 'Therapy of Ischemic Cerebral Vascular Disease'. Together they form a unique fingerprint.

Cite this

@article{fcc46849c0694dcb8d6a657c4368cfae,

title = "Therapy of Ischemic Cerebral Vascular Disease",

abstract = "To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.",

author = "Pincus, {Martin M.} and Michael Hennerici and Wolfgang Rautenberg and Saidman, {Lawrence J.} and Kistler, {J. P.} and Ropper, {Allan H.} and Heros, {Roberto C.}",

year = "1984",

month = oct,

day = "25",

doi = "10.1056/NEJM198410253111715",

language = "English (US)",

volume = "311",

pages = "1124--1125",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "17",

}

TY - JOUR

T1 - Therapy of Ischemic Cerebral Vascular Disease

AU - Pincus, Martin M.

AU - Hennerici, Michael

AU - Rautenberg, Wolfgang

AU - Saidman, Lawrence J.

AU - Kistler, J. P.

AU - Ropper, Allan H.

AU - Heros, Roberto C.

PY - 1984/10/25

Y1 - 1984/10/25

N2 - To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

AB - To the Editor: A patient who has had a transient ischemic attack is by definition neurologically intact, at least when seen 24 hours after the event. The very concept that he has a disease — namely, threatened stroke — is based on statistical reasoning. In fact, several studies have shown that the majority of patients do not go on to have a completed stroke over the next year. In order to prove that any proposed therapy is better than “doing nothing,” it would seem to be incumbent on the proponents to prove that the probability of stroke or of a.

UR - http://www.scopus.com/inward/record.url?scp=0021150084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021150084&partnerID=8YFLogxK

U2 - 10.1056/NEJM198410253111715

DO - 10.1056/NEJM198410253111715

M3 - Letter

C2 - 6482925

AN - SCOPUS:0021150084

VL - 311

SP - 1124

EP - 1125

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 17

ER -